Unexpected cardiovascular risk with Amgen and UCB's romosozumab and longer timeline for potential U.S. approval bodes well for Radius Health's Tymlos; shares ahead 18% premarket [Seeking A...
Radius Recycling, Inc. - Class A (RDUS)
Last radius recycling, inc. - class a earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.radiuspharm.com
Company Research
Source: Seeking Alpha
Radius Health (NASDAQ: RDUS ) is up premarket on light volume after Amgen's announcement of late-stage results for osteoporosis candidate EVENITY (romosozumab) that included an unexpected cardiovascular safety signal. The FDA recently approved (April) Radius' TYMLOS (abaloparatide) for the same population of high risk postmenopausal women. It carries no increased cardiovascular risk but its package insert has a boxed warning about an increased risk of osteosarcoma. Previously: Amgen's and UCB's romosozumab successful in late-stage osteoporosis study but cardiovascular safety signal observed; Amgen down 2% premarket (May 22) Now read: Evaluating The Strength Of Concert Pharmaceuticals' Broad Patent Estate Covering Deuterated Compounds »
Show less
Read more
Impact Snapshot
Event Time:
RDUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDUS alerts
High impacting Radius Recycling, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RDUS
News
- Radius Announces Presentation of Data on TYMLOS (abaloparatide) at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases Accesswire
- Radius Recycling, Inc. (NASDAQ: RDUS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Radius Recycling Reports Second Quarter Fiscal 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Radius Recycling Reports Second Quarter Fiscal 2024 Financial ResultsGlobeNewswire
- Second Quarter Fiscal 2024 Preliminary Results and Announcement of Earnings Date [Yahoo! Finance]Yahoo! Finance